ライフサイエンスコーパス: lipid nanoparticle

1 rimary hepatocytes as mRNA encapsulated in a lipid nanoparticle.

2 structural proteins that is delivered via a lipid nanoparticle.

3 rmation of oxidatively and physically stable lipid nanoparticles.

4 SSOs were delivered in vivo using lipid nanoparticles.

5 lycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles.

6 ylene glycol (PEG) liposomal drugs, and mRNA lipid nanoparticles.

7 ently and specifically to the pancreas using lipid nanoparticles.

8 rs, focusing on adeno-associated viruses and lipid nanoparticles.

9 to redesign PsCas9 for in vivo editing using lipid nanoparticles.

10 YC mice, which develop hepatoblastoma, using lipid nanoparticles.

11 dy VRC01 are generated and encapsulated into lipid nanoparticles.

12 ical trials is an mRNA vaccine delivered via lipid nanoparticles.

13 than the siRNA doses typically delivered via lipid nanoparticles.

14 ived from the leukocyte plasma membrane into lipid nanoparticles.

15 livery to the lungs using degradable polymer-lipid nanoparticles.

16 overed that 4-(N)-stearoyl gemcitabine solid lipid nanoparticles (4-(N)-GemC18-SLNs) can overcome mul

17 liposomes, polymeric nanoparticles and solid lipid nanoparticles) all containing equal concentrations

18 The vitamin C lipid nanoparticles allow the specific accumulation of A

19 Here we present an optimized lipid nanoparticle and a CCR2-silencing short interferin

20 and lentiviral vectors for gene therapy and lipid nanoparticle and other non-viral vectors for nucle

21 hepatitis C virus (HCV) were formulated into lipid nanoparticles and administered intravenously to HC

22 two well-established siRNA delivery systems, lipid nanoparticles and cholesterol conjugated-siRNAs.

23 high antigen loading (> 85%) with liposomes, lipid nanoparticles and emulsions being <200 nm, whilst

24 complexation, nanoparticulate systems (solid lipid nanoparticles and nanostructured lipid carriers),

25 nterfering RNA (siRNA) delivered via passive lipid nanoparticles and other delivery vehicles reaches

26 nd carrier-assisted delivery systems such as lipid nanoparticles and protein/peptide conjugates, the

27 classes of siRNA delivery systems, including lipid nanoparticles and siRNA conjugates, are designed t

28 ted siRNA interference (RNAi) therapeutic in lipid nanoparticles and subsequent approvals of five mor

29 e components, as seen in stable nucleic-acid-lipid nanoparticles and the cyclodextrin polymer, will b

30 incipal structural protein of HDL that forms lipid nanoparticles, and ApoM, a chaperone for the bioac

31 vivo gene editing, including viral vectors, lipid nanoparticles, and virus-like particles.

32 te their wide application in human diseases, lipid nanoparticles are rarely used in agricultural appl

33 targeting (SORT) wherein multiple classes of lipid nanoparticles are systematically engineered to exc

34 y-elicited processes, we generate a bridging-lipid nanoparticle (B-LNP) that engages tumor-associated

35 The leading lipid nanoparticle, BAMEA-O16B, represents one of the mo

36 Afterward, a lipid nanoparticle-based long non-coding RNA (lncRNA) th

37 lease of siRNAs, formulated in lipoplexes or lipid nanoparticles, by live-cell imaging and correlated

38 caffold functionalized with carvacrol-loaded lipid nanoparticles (CA-LNPs) to improve bone health.

39 d 4-(N)-stearoyl cytarabine carried by solid lipid nanoparticles can also overcome the resistance.

40 -encoded Cas13a and guide RNAs formulated in lipid nanoparticles can be used to treat dengue virus (D

41 ase editors that are delivered in vivo using lipid nanoparticles can efficiently and precisely modify

42 tropism and tissue distribution of mRNA and lipid nanoparticles can lead to toxicity, and their poss

43 atform can efficiently down select effective lipid nanoparticle candidates from a lipid nanoparticle

44 oligonucleotide (ASO) technologies involving lipid nanoparticle carriers or N-acetylgalactosamine fra

45 erfering RNA (siRNA) has been realized using lipid nanoparticles, cationic complexes, inorganic nanop

46 s form stable LNPs, herein named constrained lipid nanoparticles (cLNPs).

47 ce, we encapsulated VSB in COG133-conjugated lipid nanoparticles (COG133-LNPs) to circumvent the bloo

48 tained by developing a novel system based on lipid nanoparticles conjugated with an anti-CD38 monoclo

49 First, one type of lipid nanoparticle containing CD40 ligand mRNA induces r

50 e, we explore the reactivation capacity of a lipid nanoparticle containing Tat mRNA (Tat-LNP) in CD4

51 achieved through systemic administration of lipid nanoparticles containing ARCUS-POL mRNA.

52 escribe an approach using platelet-optimized lipid nanoparticles containing mRNA (mRNA-LNP) to enable

53 unotherapy for atherosclerosis, we generated lipid nanoparticles decorated with an anti-CLEC9A antibo

54 we immediately began to develop a customized lipid nanoparticle-delivered base-editing therapy.

55 mates and highlight the rapid development of lipid-nanoparticle-delivered siRNA as a countermeasure a

56 utaneous tissue nanotransfection or targeted lipid nanoparticle delivery of anti-sense oligonucleotid

57 ion of lumacaftor and ivacaftor delivered by lipid nanoparticles directly into the lungs was highly e

58 All alpha-tocopherol loaded solid lipid nanoparticles dispersions showed stability with no

59 After recrystallization of solid lipid nanoparticles, dispersions were evaluated until 60

60 e development of theranostic dendrimer-based lipid nanoparticle (DLNP) system containing PEGylated BO

61 The DTX-loaded cationic solid lipid nanoparticles (DSLN-CSG) were coated with an anion

62 ing small circular RNAs (circRNAs) loaded in lipid nanoparticles elicit potent and durable T cell res

63 mbrane SOSIP (SOSIP-TM) delivered as an mRNA-lipid nanoparticle elicited more potent neutralizing res

64 at capturing and expressing mRNA vectored by lipid nanoparticles, enabling the assessment of response

65 -protein-encoding, nucleoside-modified mRNA, lipid nanoparticle encapsulated vaccine that we report t

66 ouse model (B6.Mecp2(Tg1)), spleen-targeting lipid nanoparticles encapsulated with antisense oligonuc

67 the vaccine consists of lymph-node-targeting lipid nanoparticles encapsulated with tumour antigens pr

68 A lipid nanoparticle-encapsulated messenger RNA (mRNA) for

69 We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine en

70 A lipid nanoparticle-encapsulated mRNA-based RSV vaccine (

71 The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that

72 ersal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA

73 Here we investigated the lipid nanoparticle-encapsulated self-replicating RNA (sr

74 detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRN

75 EGF) in hepatocytes via nucleoside-modified, lipid-nanoparticle-encapsulated mRNA (mRNA-LNP) delivery

76 ingle low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA

77 Here we show that lipid-nanoparticle-encapsulated short interfering RNAs (

78 A lipid nanoparticle encapsulating nucleoside-modified mRN

79 ltiply adjuvanted mRNA vaccine consisting of lipid nanoparticles encapsulating an mRNA-encoded antige

80 A single administration of lipid nanoparticles encapsulating mRNA encoding this epi

81 Delivery of mRNA-lipid nanoparticles encoding BD55-1205-IgG in mice resul

82 l transfer, conditional Siglecf knockout and lipid nanoparticles facilitating local SiglecF+ neutroph

83 ctional assessment using anti-CD5-conjugated lipid nanoparticles for codelivering CD19 CAR mRNA (mCAR

84 the formulation and delivery of mRNA-loaded lipid nanoparticles for immunization against the SARS-CO

85 g platform to identify optimized plasmid DNA lipid nanoparticles for liver-targeted transgene express

86 After treatment with lipid nanoparticles formulated with base editing reagent

87 nobodies) approach, which utilizes inhalable lipid nanoparticles formulated with budesonide (iLNP(BUD

88 19 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA t

89 , we report the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, P

90 d over 25 days after a single treatment of a lipid nanoparticle-formulated siRNA targeting luciferase

91 Here we show that two doses of a lipid nanoparticle-formulated unmodified mRNA vaccine en

92 age to receive either placebo or one of two lipid nanoparticle-formulated, nucleoside-modified RNA v

93 BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA v

94 BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA v

95 BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA

96 mately resulted in the timely development of lipid nanoparticle formulations for COVID-19 vaccine del

97 d on these findings, we developed multiagent lipid nanoparticle formulations of these drugs that not

98 Using lipid nanoparticle formulations of these enhanced sgRNAs

99 are challenging to access using traditional lipid nanoparticle formulations.

100 Lipid nanoparticles functionalized with targeting peptid

101 integrated analysis suggested that cationic lipid nanoparticles, functionalized with octa-arginine p

102 of the extended half-life mouse and rat mRNA lipid nanoparticles generated measurable GM-CSF plasma c

103 first- and second-generation formulations of lipid nanoparticles, generating ALN-TTR01 and ALN-TTR02,

104 mobilization of hyaluronic acid-coated solid lipid nanoparticles (HA-SLNs)-used here for the first ti

105 id pK(a) in the in vivo delivery of siRNA by lipid nanoparticles has been studied with a large number

106 Lipid nanoparticles have been used for carrying differen

107 tems have been reported, and some, including lipid nanoparticles, have exhibited clinical success.

108 biome enhances CD8+ T cell responses to mRNA lipid nanoparticle immunization, the microbiome suppress

109 Human hASL mRNA encapsulated in lipid nanoparticles improved glutathione metabolism and

110 o determine the biodistribution of different lipid nanoparticles in plant tissues.

111 order the effectiveness of siRNA delivery by lipid nanoparticles in vivo.

112 we identified species-dependent responses to lipid nanoparticles, including mRNA translation and endo

113 form, nucleoside-modified mRNA formulated in lipid nanoparticles, increased the durability and breadt

114 BAMEA-O16B, a lipid nanoparticle integrated with disulfide bonds, can

115 Lactosylated gramicidin-containing lipid nanoparticles (Lac-GLN) were developed for deliver

116 fective lipid nanoparticle candidates from a lipid nanoparticle library of over 1000 formulations.

117 ronmental contaminants via permeation across lipid nanoparticles (liposomes) as a mimicry of biologic

118 genated palm oil (HPO) as compared to liquid lipid nanoparticles (LLNs) with pure MCT.

119 ponses in female Balb/c mice, utilizing mRNA lipid nanoparticle (LNP) and protein-based PHC nanoparti

120 tissue mechanics via a multiplexed dendrimer lipid nanoparticle (LNP) approach involving co-delivery

121 RS-CoV-2 spike protein encapsulated within a lipid nanoparticle (LNP) as a vaccine.

122 The development of lipid nanoparticle (LNP) based small interfering RNA (si

123 Adding a cationic helper lipid to a lipid nanoparticle (LNP) can increase lung delivery and

124 nd within a multicomponent colloid such as a lipid nanoparticle (LNP) can influence its activity in v

125 ere, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprot

126 c against SARS-CoV-2 infection using a novel lipid nanoparticle (LNP) delivery system.

127 Designing lipid nanoparticle (LNP) delivery systems with specific

128 We engineered a lipid nanoparticle (LNP) encapsulated modified mRNA vacc

129 x manufacturing, including their reliance on lipid nanoparticle (LNP) encapsulation.

130 a-associated TAMCs, we rationally designed a lipid nanoparticle (LNP) formulation surface-functionali

131 manding rigorous monitoring of impurities in lipid nanoparticle (LNP) formulations.

132 Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA vaccine candidate, and tes

133 Here, we develop an optimized lipid nanoparticle (LNP) platform for circRNA delivery t

134 n, synthesis, and biological evaluation of a lipid nanoparticle (LNP) system that can encapsulate mRN

135 Here, we develop an inhalable lipid nanoparticle (LNP) system that enables simultaneou

136 COVID-19 vaccines, which are delivered using lipid nanoparticle (LNP) systems.

137 By using a lipid nanoparticle (LNP) targeting the receptor CD117 an

138 targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased poten

139 ormulations for a SARS-CoV-2 saRNA ionizable lipid nanoparticle (LNP) to help reduce dependence on th

140 by the rapid lethality of the model and poor lipid nanoparticle (LNP) uptake into neonatal mouse live

141 Here, we generate an mRNA lipid nanoparticle (LNP) vaccine encoding the hemaggluti

142 Given the success of the mRNA-lipid nanoparticle (LNP) vaccine platform to vaccinate a

143 Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA,

144 ases in mice receiving in vivo delivery with lipid nanoparticle (LNP), indicating their great potenti

145 Here, we show that vaccination with a lipid nanoparticle (LNP)-encapsulated DNA vaccine can pa

146 e describe a molecular adjuvant comprising a lipid nanoparticle (LNP)-encapsulated mRNA encoding inte

147 in (lacking AD-3) with squalene adjuvant, or lipid nanoparticle (LNP)-encapsulated nucleoside-modifie

148 tune fibrinogen expression by administering lipid nanoparticle (LNP)-encapsulated small interfering

149 rabbits and nonhuman primates injected with lipid nanoparticle (LNP)-formulated Andes virus or Zika

150 Herein, we develop a lipid nanoparticle (LNP)-formulated mRNA-based T-cell-in

151 g these findings to cancer therapy, we use a lipid nanoparticle (LNP)-mediated mRNA delivery approach

152 Gene transfection via lipid nanoparticle (LNP)-mRNA complexes have tremendous

153 Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and

154 oro-modified derivative (dsP21-322-2'F) into lipid nanoparticles (LNP) for intravesical delivery.

155 iated combinatorial approach using targeting lipid nanoparticles (LNP) for the treatment of obesity.

156 nistered K-Ras-beta-catenin mice with EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate

157 uridine-modified mRNA vaccines formulated in lipid nanoparticles (LNP) targeting the glycoproteins (G

158 A virus M2 ectodomain (M2e), encapsulated in lipid nanoparticles (LNP), capable of inducing cross-lin

159 to enhance endosomal escape in a context of lipid nanoparticles (LNP), here, we provide the first re

160 zed ectodomain spike protein encapsulated in lipid nanoparticles (LNP).

161 apy, mRNA vaccines-typically encapsulated in lipid nanoparticles (LNPs) 100-200 nm in size-enable del

162 Finally, we developed a lipid nanoparticles (LNPs) and chemically modified small

163 ns (RNPs) were encapsulated in mulberry leaf lipid nanoparticles (LNPs) and formulated with d-alpha-t

164 ting plasminogen packaged in clinically used lipid nanoparticles (LNPs) and tested it to determine wh

165 Lipid nanoparticles (LNPs) are efficient carriers for sh

166 ies of alkenyl amino alcohol (AAA) ionizable lipid nanoparticles (LNPs) capable of delivering human m

167 Four-component lipid nanoparticles (LNPs) consisting of ionizable lipid

168 Four-component lipid nanoparticles (LNPs) containing ionizable lipids,

169 HSCs have been modified in vivo using lipid nanoparticles (LNPs) decorated with targeting moie

170 geneity influences the efficiency with which lipid nanoparticles (LNPs) deliver messenger RNA therapi

171 ased system designed to measure how over 100 lipid nanoparticles (LNPs) deliver mRNA that functions i

172 ajor focus in the past decade with ionizable lipid nanoparticles (LNPs) emerging as a clinically-vali

173 then we developed CH6 aptamer-functionalized lipid nanoparticles (LNPs) encapsulating osteogenic plec

174 ed to the protein or as excipients) and that lipid nanoparticles (LNPs) encapsulating RNPs can be opt

175 zed nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNPs) encoding murine Vascular Endo

176 nomedicine-based strategy that utilizes mRNA lipid nanoparticles (LNPs) encoding only the N-terminus

177 Food and Drug Administration (FDA)-approved lipid nanoparticles (LNPs) exhibit reliable efficiency i

178 However, nebulized mRNA lipid nanoparticles (LNPs) face several unique challenge

179 preparation of high-quality siRNA-containing lipid nanoparticles (LNPs) for a large number of materia

180 ct lead candidates for in vivo evaluation of lipid nanoparticles (LNPs) for systemic small interferin

181 Libraries of ionizable lipid nanoparticles (LNPs) have been designed to encapsu

182 sulation within biodegradable liver-targeted lipid nanoparticles (LNPs) have potentially enabled a ne

183 Delivery of an mRNA formulated with lipid nanoparticles (LNPs) induces robust humoral and ce

184 Delivery of exogenous mRNA using lipid nanoparticles (LNPs) is a promising strategy for t

185 For example, mRNA delivered by lipid nanoparticles (LNPs) is being considered to treat

186 Compared to lipid nanoparticles (LNPs) lacking a surface-bound DNA s

187 However, existing lipid nanoparticles (LNPs) primarily accumulate in the l

188 n, delivery of modified mRNA encapsulated in lipid nanoparticles (LNPs) provides a framework for trea

189 In contrast, repRNA delivered by lipid nanoparticles (LNPs) showed generalized biodistrib

190 Hbb(th3/+)) with Tmprss6 siRNA formulated in lipid nanoparticles (LNPs) that are preferentially taken

191 nvestigation of the pH-dependent behavior of lipid nanoparticles (LNPs) through Monte Carlo simulatio

192 re suitable for delivery as RNA molecules by lipid nanoparticles (LNPs) to cell lines, primary neuron

193 Here, we employed lipid nanoparticles (LNPs) to deliver either non-specifi

194 ltiparametric approach for the evaluation of lipid nanoparticles (LNPs) to identify relationships bet

195 erage Spleen Selective ORgan Targeted (SORT) Lipid Nanoparticles (LNPs) to produce CAR T cells in sit

196 d PCCB (hPCCB) encapsulated in biodegradable lipid nanoparticles (LNPs) to produce functional PCC enz

197 Here, we develop lipid nanoparticles (LNPs) to provide safe and effective

198 Advancements in nanotechnology utilize lipid nanoparticles (LNPs) to transport and deliver ther

199 mic, in vivo, nonviral mRNA delivery through lipid nanoparticles (LNPs) to treat a Factor IX (FIX)-de

200 f short interfering RNA (siRNA) delivered in lipid nanoparticles (LNPs) using cellular trafficking pr

201 sequence- and base-optimized BCMA mRNA into lipid nanoparticles (LNPs) using next-generation ionizab

202 m of this work was to study the formation of lipid nanoparticles (LNPs) with low (corn and olive oil)

203 nt helper lipids to formulate four-component lipid nanoparticles (LNPs), achieving respective lung- a

204 pid-based RNA delivery systems, particularly lipid nanoparticles (LNPs), have been extensively studie

205 stems with structures that can be similar to lipid nanoparticles (LNPs), it is hypothesized that LNPs

206 degradation and achieve efficient delivery, lipid nanoparticles (LNPs), particularly those based on

207 mRNAs, etc.) and formulation methods (i.e., lipid nanoparticles (LNPs), polymers, peptides, etc.) ha

208 to improve the delivery of mRNA drugs using lipid nanoparticles (LNPs), the clinically approved chem

209 Next, FXN mRNA, in the form of lipid nanoparticles (LNPs), was administered intravenous

210 ivery of short interfering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifyi

211 s virus glycoprotein (RVG) peptide decorated lipid nanoparticles (LNPs), which showed 4.9 +/- 0.1 and

212 RNA delivery can be achieved using ionizable lipid nanoparticles (LNPs).

213 of size variants for large nucleic acids and lipid nanoparticles (LNPs).

214 vailable for formulating and evaluating mRNA lipid nanoparticles (LNPs).

215 (DEN-80E) formulated with ionizable cationic lipid nanoparticles (LNPs).

216 ing capsids, engineered viral-like proteins, lipid nanoparticles (LNPs)] and novel therapeutic strate

217 s delivered using 4 different chemistries of lipid nanoparticles (LNPs, the frontrunner class of drug

218 as a consequence of treating the cells with lipid nanoparticles, LNPs.

219 After intravenous injection, up to 90% of lipid nanoparticles loaded with small interfering RNA to

220 vanced liver fibrosis that received cationic lipid nanoparticles loaded with small interfering RNA to

221 Our lipid nanoparticles loaded with small interfering RNA to

222 rgos: a protein, bovine serum albumin, and a lipid nanoparticle, low-density lipoprotein.

223 e more than that induced by the FDA-approved lipid nanoparticle material MC3 in vaccinated mice.

224 derivatives of nucleoside analogs into solid lipid nanoparticles may represent a platform technology

225 ved microRNAs stabilized by species-specific lipid nanoparticles mediate interkingdom communication t

226 Here, we combine lipid nanoparticle-mediated delivery of Cas9 mRNA with a

227 -derived organoids, but could be rescued via lipid nanoparticle-mediated FXR WT mRNA delivery, indica

228 enerated FAH(+) hepatocytes in the liver via lipid-nanoparticle-mediated delivery of a chemically mod

229 Here we show that lipid-nanoparticle-mediated gene editing in the lung and

230 Current nucleoside-modified RNA lipid nanoparticle (modmRNA-LNP) technology has successf

231 a billion of vaccinations with messenger RNA-lipid nanoparticle (mRNA-LNP) based SARS-CoV-2 vaccines,

232 lutinin (HA) following initial messenger RNA-lipid nanoparticle (mRNA-LNP) vaccination, Prime and HA.

233 an E1/sE2(F442NYT) nucleoside-modified mRNA-lipid nanoparticle (mRNA-LNP) vaccine resulted in improv

234 e nucleoside-modified mRNA encapsulated into lipid nanoparticles (mRNA-LNPs) in acutely or chronicall

235 nnovations underlying mRNA covid-19 vaccines-lipid nanoparticle, mRNA synthesis or modification, pref

236 Here we combine lipid nanoparticle-mRNA formulations and dendritic cell

237 y systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions.

238 Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect this adjuvant

239 t nanoprecipitate is encapsulated inside the lipid nanoparticles (NPs) modified with the PEGylated am

240 We determined that a single dose of a lipid nanoparticle nucleoside-modified messenger RNA vac

241 Identical siRNAs delivered in lipid nanoparticles or as GalNAc conjugates were dose-ad

242 ids (ICLs: DiD, DiI) formulated in PEGylated lipid nanoparticle (PLN) exhibit highly efficient penetr

243 ery system for siRNA based on hybrid polymer-lipid nanoparticles (PLNs) and combined this system with

244 roteins from DENV serotype 1 encapsulated in lipid nanoparticles (prM/E mRNA-LNP).

245 TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the t

246 NP-718m siRNA in lipid nanoparticles provided 100% protection against MAR

247 FXIII-B with siRNA in mice and rabbits using lipid nanoparticles resulted in a sustained and controll

248 ally, intratumor delivery of CCL5 mRNA using lipid nanoparticles significantly inhibited tumor growth

249 lutions, whilst in the second approach solid lipid nanoparticle (SLN) dispersions of DHA, were first

250 develop a novel drug delivery system, solid lipid nanoparticle (SLN), capable of delivering high pay

251 straints for practical applications of solid lipid nanoparticles (SLN) as oral delivery vehicles.

252 and omega-3 fish oil, (ii) tristearin solid lipid nanoparticles (SLN), and (iii) omega-3 fish oil-in

253 oil--on the structural arrangement of solid lipid nanoparticles (SLN).

254 no delivery systems (nanoemulsions-NE, solid lipid nanoparticles-SLN and nanostructured lipid carrier

255 eveloped an innovative approach, using solid lipid nanoparticles (SLNs) and dissolving microneedles (

256 Solid lipid nanoparticles (SLNs) are emulsion-based carriers o

257 ic NPs, and lipid-based NPs (Liposome, solid-lipid nanoparticles (SLNs), and nanostructured lipid car

258 ent-free approaches like styrene-maleic acid lipid nanoparticles (SMALPs) are used.

259 port improved Lung Selective Organ Targeting Lipid Nanoparticles (SORT LNPs) for efficient delivery o

260 with a four-step workflow to develop inhaled lipid nanoparticles specifically for pulmonary mRNA deli

261 ic acid delivery approaches to create CRISPR lipid nanoparticle-spherical nucleic acids (LNP-SNAs) th

262 hen complexed with silicon-stabilized hybrid lipid nanoparticles (sshLNP), and applied topically twic

263 NA nanoparticles, the identified plasmid DNA lipid nanoparticles successfully deliver transgenes and

264 ypothesized that CPA solubilized in a liquid-lipid nanoparticle system (CPA-LLP) for intravenous inje

265 Further development of the lipid nanoparticle technology has the potential to yield

266 n-human primate studies to optimize a GalNAc-Lipid nanoparticle that allows for low-density lipoprote

267 Further, we developed a lipid nanoparticle that targets the pulmonary endotheliu

268 The described theranostic lipid nanoparticles that combine mRNA delivery and NIR i

269 are constructed by transfection of vitamin C lipid nanoparticles that deliver antimicrobial peptide a

270 we report on a series of bone-marrow-homing lipid nanoparticles that deliver mRNA to a broad group o

271 b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike gl

272 describe an approach for engineering peptide-lipid nanoparticles that function similarly to high-dens

273 Building on these results, we developed lipid nanoparticles that preferentially target activated

274 After delivery by lipid nanoparticles, the degradation of POI by pre-fused

275 the measurement of other NEP forms (such as lipid nanoparticle therapeutics) with some modifications

276 and therapeutic intranasal administration of lipid-nanoparticle TIPs durably suppressed SARS-CoV-2 by

277 hodology that allows engineering of modified lipid nanoparticles to efficiently deliver RNPs into cel

278 Herein, we conceive a series of lipid nanoparticles to reprogram ASCs with durable prote

279 sphatidylcholine, as a minimalist model of a lipid nanoparticle, to evaluate both the interaction ene

280 Formulated lncRNA-TARID-laden lipid nanoparticles up-regulated Tcf21 expression in epi

281 h nucleic acid cargos and the development of lipid nanoparticles using ionizable cationic lipids.

282 MPER-derived peptides were incorporated into lipid nanoparticles using natural and designed TM domain

283 eneration following viral infection and mRNA-lipid nanoparticle vaccination.

284 Here, we demonstrate that an mRNA-lipid nanoparticle vaccine encoding a set of four highly

285 19ISP is a nucleoside-modified mRNA-lipid nanoparticle vaccine that targets 19 Ixodes scapul

286 e the development of protective DNA and mRNA-lipid nanoparticle vaccines targeting hemagglutinin and

287 as compared with adeno-associated viral and lipid nanoparticle VEGF-A gene therapy modalities, murin

288 A lipid nanoparticle was developed that allowed nuclear ta

289 Also, mRNA formulation in lipid nanoparticles was assessed for systemic delivery i

290 e of hepatitis C virus (HCV) formulated with lipid nanoparticles, was able to suppress viral replicat

291 Gadolinium lipid nanoparticles were able to identify tumor-induced

292 Bone-marrow-homing lipid nanoparticles were also able to achieve Cre-recomb

293 The multivalent peptide-lipid nanoparticles were also remarkably stable toward e

294 Lung-, spleen- and liver-targeted SORT lipid nanoparticles were designed to selectively edit th

295 conditions (e.g., pH and temperature), solid lipid nanoparticles were prepared by the dilution of wat

296 different doxorubicin and paclitaxel-loaded lipid nanoparticles were prepared.

297 PKU and PXE, we show that when formulated in lipid nanoparticles with ABE messenger RNA, selected hyb

298 Here we report that combining bioreducible lipid nanoparticles with negatively supercharged Cre rec

299 Barcoding lipid nanoparticles with peptide-encoding mRNAs may faci

300 s two-color STORM recordings of cargo-loaded lipid nanoparticles without fiducials, demonstrating the